Analyst Reco. BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-15 EDT			5-day change	1st Jan Change
0.617 ^USD	-4.33%		-6.49%	-60.70%

04-17	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
04-10	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating	23-09-15	MT
BIOLINERX : HC Wainwright Adjusts BioLineRx' Price Target to $19 from $22, Keeps Buy Rating	21-02-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW